Exome first approach to reduce diagnostic costs and time - retrospective analysis of 111 individuals with rare neurodevelopmental disorders.
Journal
European journal of human genetics : EJHG
ISSN: 1476-5438
Titre abrégé: Eur J Hum Genet
Pays: England
ID NLM: 9302235
Informations de publication
Date de publication:
01 2022
01 2022
Historique:
received:
15
06
2021
accepted:
04
10
2021
revised:
22
09
2021
pubmed:
26
10
2021
medline:
24
3
2022
entrez:
25
10
2021
Statut:
ppublish
Résumé
This single-center study aims to determine the time, diagnostic procedure, and cost saving potential of early exome sequencing in a cohort of 111 individuals with genetically confirmed neurodevelopmental disorders. We retrospectively collected data regarding diagnostic time points and procedures from the individuals' medical histories and developed criteria for classifying diagnostic procedures in terms of requirement, followed by a cost allocation. All genetic variants were re-evaluated according to ACMG recommendations and considering the individuals' phenotype. Individuals who developed first symptoms of their underlying genetic disorder when Next Generation Sequencing (NGS) diagnostics were already available received a diagnosis significantly faster than individuals with first symptoms before this cutoff. The largest amount of potentially dispensable diagnostics was found in genetic, metabolic, and cranial magnetic resonance imaging examinations. Out of 407 performed genetic examinations, 296 (72.7%) were classified as potentially dispensable. The same applied to 36 (27.9%) of 129 cranial magnetic resonance imaging and 111 (31.8%) of 349 metabolic examinations. Dispensable genetic examinations accounted 302,947.07€ (90.2%) of the total 335,837.49€ in potentially savable costs in this cohort. The remaining 32,890.42€ (9.8%) are related to non-required metabolic and cranial magnetic resonance imaging diagnostics. On average, the total potentially savable costs in our study amount to €3,025.56 per individual. Cost savings by first tier exome sequencing lie primarily in genetic, metabolic, and cMRI testing in this German cohort, underscoring the utility of performing exome sequencing at the beginning of the diagnostic pathway and the potential for saving diagnostic costs and time.
Identifiants
pubmed: 34690354
doi: 10.1038/s41431-021-00981-z
pii: 10.1038/s41431-021-00981-z
pmc: PMC8738730
doi:
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
117-125Informations de copyright
© 2021. The Author(s).
Références
Kumar P, Radhakrishnan J, Chowdhary MA, Giampietro PF. Prevalence and Patterns of Presentation of Genetic Disorders in a Pediatric Emergency Department. Mayo Clin Proc. 2001;76:777–83. https://doi.org/10.4065/76.8.777
doi: 10.4065/76.8.777
pubmed: 11499815
Yoon PW. Contribution of Birth Defects and Genetic Diseases to Pediatric Hospitalizations: a Population-Based Study. Arch Pediatr Adolesc Med. 1997;151:1096 https://doi.org/10.1001/archpedi.1997.02170480026004
doi: 10.1001/archpedi.1997.02170480026004
pubmed: 9369870
Gilissen C, Hehir-Kwa JY, Thung DT, van de Vorst M, van Bon BWM, Willemsen MH, et al. Genome sequencing identifies major causes of severe intellectual disability. Nature. 2014;511:344–7. https://doi.org/10.1038/nature13394
doi: 10.1038/nature13394
pubmed: 24896178
Aaberg KM, Gunnes N, Bakken IJ, Lund Søraas C, Berntsen A, Magnus P, et al. Incidence and Prevalence of Childhood Epilepsy: a Nationwide Cohort Study. Pediatrics. 2017;139:e20163908 https://doi.org/10.1542/peds.2016-3908
doi: 10.1542/peds.2016-3908
pubmed: 28557750
Wang J, Lin Z-J, Liu L, Xu H-Q, Shi Y-W, Yi Y-H, et al. Epilepsy-associated genes. Seizure. 2017;44:11–20. https://doi.org/10.1016/j.seizure.2016.11.030
doi: 10.1016/j.seizure.2016.11.030
pubmed: 28007376
Hanly C, Shah H, Au PYB, Murias K. Description of neurodevelopmental phenotypes associated with 10 genetic neurodevelopmental disorders: a scoping review. Clin Genet. 2021;99:335–46. https://doi.org/10.1111/cge.13882
doi: 10.1111/cge.13882
pubmed: 33179249
Carmichael N, Tsipis J, Windmueller G, Mandel L, Estrella E. “Is it Going to Hurt?”: the Impact of the Diagnostic Odyssey on Children and Their Families. J Genet Couns. 2015;24:325–35. https://doi.org/10.1007/s10897-014-9773-9
doi: 10.1007/s10897-014-9773-9
pubmed: 25277096
Gonzaludo N, Belmont JW, Gainullin VG, Taft RJ. Estimating the burden and economic impact of pediatric genetic disease. Genet Med. 2019;21:1781–9. https://doi.org/10.1038/s41436-018-0398-5
doi: 10.1038/s41436-018-0398-5
pubmed: 30568310
McCandless SE, Brunger JW, Cassidy SB. The Burden of Genetic Disease on Inpatient Care in a Children’s Hospital. Am J Hum Genet. 2004;74:121–7. https://doi.org/10.1086/381053
doi: 10.1086/381053
pubmed: 14681831
Arim RG, Miller AR, Guèvremont A, Lach LM, Brehaut JC, Kohen DE. Children with neurodevelopmental disorders and disabilities: a population-based study of healthcare service utilization using administrative data. Dev Med Child Neurol. 2017;59:1284–90. https://doi.org/10.1111/dmcn.13557
doi: 10.1111/dmcn.13557
pubmed: 28905997
Strzelczyk A, Reese JP, Dodel R, Hamer HM. Cost of epilepsy: a systematic review. PharmacoEconomics. 2008;26:463–76. https://doi.org/10.2165/00019053-200826060-00002
doi: 10.2165/00019053-200826060-00002
pubmed: 18489198
Schofield D, Rynehart L, Shresthra R, White SM, Stark Z. Long-term economic impacts of exome sequencing for suspected monogenic disorders: diagnosis, management, and reproductive outcomes. Genet Med. 2019;21:2586–93. https://doi.org/10.1038/s41436-019-0534-x
doi: 10.1038/s41436-019-0534-x
pubmed: 31110331
Dixon-Salazar TJ, Silhavy JL, Udpa N, Schroth J, Bielas S, Schaffer AE, et al. Exome Sequencing Can Improve Diagnosis and Alter Patient Management. Sci Transl Med. 2012;4:138ra78–138ra78. https://doi.org/10.1126/scitranslmed.3003544
doi: 10.1126/scitranslmed.3003544
pubmed: 22700954
pmcid: 4442637
Graungaard AH, Skov L. Why do we need a diagnosis? A qualitative study of parents? experiences, coping and needs, when the newborn child is severely disabled. Child Care Health Dev. 2007;33:296–307. https://doi.org/10.1111/j.1365-2214.2006.00666.x
doi: 10.1111/j.1365-2214.2006.00666.x
pubmed: 17439444
Iglesias A, Anyane-Yeboa K, Wynn J, Wilson A, Truitt Cho M, Guzman E, et al. The usefulness of whole-exome sequencing in routine clinical practice. Genet Med. 2014;16:922–31. https://doi.org/10.1038/gim.2014.58
doi: 10.1038/gim.2014.58
pubmed: 24901346
Srivastava S, Cohen JS, Vernon H, Barañano K, McClellan R, Jamal L, et al. Clinical whole exome sequencing in child neurology practice: WES in Child Neurology. Ann Neurol. 2014;76:473–83. https://doi.org/10.1002/ana.24251
doi: 10.1002/ana.24251
pubmed: 25131622
Rump P, Jazayeri O, van Dijk-Bos KK, Johansson LF, van Essen AJ, Verheij JBGM, et al. Whole-exome sequencing is a powerful approach for establishing the etiological diagnosis in patients with intellectual disability and microcephaly. BMC Med Genom. 2015;9:7 https://doi.org/10.1186/s12920-016-0167-8
doi: 10.1186/s12920-016-0167-8
Fernandez-Marmiesse A, Gouveia S, Couce ML. NGS Technologies as a Turning Point in Rare Disease Research, Diagnosis and Treatment. CMC. 2018;25:404–32. https://doi.org/10.2174/0929867324666170718101946
doi: 10.2174/0929867324666170718101946
Demos M, Guella I, DeGuzman C, McKenzie MB, Buerki SE, Evans DM, et al. Diagnostic Yield and Treatment Impact of Targeted Exome Sequencing in Early-Onset Epilepsy. Front Neurol. 2019;10:434 https://doi.org/10.3389/fneur.2019.00434
doi: 10.3389/fneur.2019.00434
pubmed: 31164858
pmcid: 6536592
Vrijenhoek T, Middelburg EM, Monroe GR, van Gassen KLI, Geenen JW, Hövels AM, et al. Whole-exome sequencing in intellectual disability; cost before and after a diagnosis. Eur J Hum Genet. 2018;26:1566–71. https://doi.org/10.1038/s41431-018-0203-6
doi: 10.1038/s41431-018-0203-6
pubmed: 29959382
pmcid: 6189079
Dillon OJ, Lunke S, Stark Z, Yeung A, Thorne N, Gaff C, et al. Exome sequencing has higher diagnostic yield compared to simulated disease-specific panels in children with suspected monogenic disorders. Eur J Hum Genet. 2018;26:644–51. https://doi.org/10.1038/s41431-018-0099-1
doi: 10.1038/s41431-018-0099-1
pubmed: 29453417
pmcid: 5945679
Zacher P, Mayer T, Brandhoff F, Bartolomaeus T, Le Duc D, Finzel M, et al. The genetic landscape of intellectual disability and epilepsy in adults and the elderly: a systematic genetic work-up of 150 individuals. Genet Med. 2021. https://doi.org/10.1038/s41436-021-01153-6 .
Lemke JR. High-Throughput Sequencing as First-Tier Diagnostics in Congenital and Early-Onset Disorders. JAMA Pediatr. 2017;171:833 https://doi.org/10.1001/jamapediatrics.2017.1970
doi: 10.1001/jamapediatrics.2017.1970
pubmed: 28759672
Srivastava S, Love-Nichols JA, Dies KA, Ledbetter DH, Martin CL, Chung WK, et al. Meta-analysis and multidisciplinary consensus statement: exomesequencing is a first-tier clinical diagnostic test for individuals withneurodevelopmental disorders. Genet Med. 2019;21:2413–21. https://doi.org/10.1038/s41436-019-0554-6
doi: 10.1038/s41436-019-0554-6
pubmed: 31182824
pmcid: 6831729
Kochinke K, Zweier C, Nijhof B, Fenckova M, Cizek P, Honti F, et al. Systematic Phenomics Analysis Deconvolutes Genes Mutated in Intellectual Disability into Biologically Coherent Modules. Am J Hum Genet. 2016;98:149–64. https://doi.org/10.1016/j.ajhg.2015.11.024
doi: 10.1016/j.ajhg.2015.11.024
pubmed: 26748517
pmcid: 4716705
Stark Z, Schofield D, Alam K, Wilson W, Mupfeki N, Macciocca I, et al. Prospective comparison of the cost-effectiveness of clinical whole-exome sequencing with that of usual care overwhelmingly supports early use and reimbursement. Genet Med. 2017;19:867–74. https://doi.org/10.1038/gim.2016.221
doi: 10.1038/gim.2016.221
pubmed: 28125081
Tan TY, Dillon OJ, Stark Z, Schofield D, Alam K, Shrestha R, et al. Diagnostic Impact and Cost-effectiveness of Whole-Exome Sequencing for Ambulant Children With Suspected Monogenic Conditions. JAMA Pediatr. 2017;171:855 https://doi.org/10.1001/jamapediatrics.2017.1755
doi: 10.1001/jamapediatrics.2017.1755
pubmed: 28759686
pmcid: 5710405
Soden SE, Saunders CJ, Willig LK, Farrow EG, Smith LD, Petrikin JE, et al. Effectiveness of exome and genome sequencing guided by acuity of illness for diagnosis of neurodevelopmental disorders. Sci Transl Med. 2014;6:265ra168–265ra168. https://doi.org/10.1126/scitranslmed.3010076
doi: 10.1126/scitranslmed.3010076
pubmed: 25473036
pmcid: 4286868
Stark Z, Tan TY, Chong B, Brett GR, Yap P, Walsh M, et al. A prospective evaluation of whole-exome sequencing as a first-tier molecular test in infants with suspected monogenic disorders. Genet Med. 2016;18:1090–6. https://doi.org/10.1038/gim.2016.1
doi: 10.1038/gim.2016.1
pubmed: 26938784
Quenez O, Cassinari K, Coutant S, Lecoquierre F, Le Guennec K, Rousseau S, et al. Detection of copy-number variations from NGS data using read depth information: a diagnostic performance evaluation. Eur J Hum Genet. 2021;29:99–109. https://doi.org/10.1038/s41431-020-0672-2
doi: 10.1038/s41431-020-0672-2
pubmed: 32591635
Berg AT, Coryell J, Saneto RP, Grinspan ZM, Alexander JJ, Kekis M, et al. Early-Life Epilepsies and the Emerging Role of Genetic Testing. JAMA Pediatr. 2017;171:863 https://doi.org/10.1001/jamapediatrics.2017.1743
doi: 10.1001/jamapediatrics.2017.1743
pubmed: 28759667
pmcid: 5710404
Miyatake S, Koshimizu E, Fujita A, Fukai R, Imagawa E, Ohba C, et al. Detecting copy-number variations in whole-exome sequencing data using the eXome Hidden Markov Model: an ‘exome-first’ approach. J Hum Genet. 2015;60:175–82. https://doi.org/10.1038/jhg.2014.124
doi: 10.1038/jhg.2014.124
pubmed: 25608832
Yubero D, Brandi N, Ormazabal A, Garcia-Cazorla À, Pérez-Dueñas B, Campistol J, et al. Targeted Next Generation Sequencing in Patients with Inborn Errors of Metabolism. PLoS ONE. 2016;11:e0156359 https://doi.org/10.1371/journal.pone.0156359
doi: 10.1371/journal.pone.0156359
pubmed: 27243974
pmcid: 4887012
Monroe GR, Frederix GW, Savelberg SMC, de Vries TI, Duran KJ, van der Smagt JJ, et al. Effectiveness of whole-exome sequencing and costs of the traditional diagnostic trajectory in children with intellectual disability. Genet Med. 2016;18:949–56. https://doi.org/10.1038/gim.2015.200
doi: 10.1038/gim.2015.200
pubmed: 26845106
Chung CCY, Leung GKC, Mak CCY, Fung JLF, Lee M, Pei SLC, et al. Rapid whole-exome sequencing facilitates precision medicine in paediatric rare disease patients and reduces healthcare costs. Lancet Regional Health - West Pac. 2020;1:100001 https://doi.org/10.1016/j.lanwpc.2020.100001
doi: 10.1016/j.lanwpc.2020.100001
Seliner B, Latal B, Spirig R. When children with profound multiple disabilities are hospitalized: A cross-sectional survey of parental burden of care, quality of life of parents and their hospitalized children, and satisfaction with family-centered care: Parents of hospitalized children with disabilities. J Spec Pediatr Nurs. 2016;21:147–57. https://doi.org/10.1111/jspn.12150
doi: 10.1111/jspn.12150
pubmed: 27319801
Salerno S, Granata C, Trapenese M, Cannata V, Curione D, Rossi Espagnet MC, et al. Is MRI imaging in pediatric age totally safe? A critical reprisal. Radio Med. 2018;123:695–702. https://doi.org/10.1007/s11547-018-0896-1
doi: 10.1007/s11547-018-0896-1
Murias K, Moir A, Myers KA, Liu I, Wei X-C. Systematic review of MRI findings in children with developmental delay or cognitive impairment. Brain Dev. 2017;39:644–55. https://doi.org/10.1016/j.braindev.2017.04.006
doi: 10.1016/j.braindev.2017.04.006
pubmed: 28457518
Fung JLF, Yu MHC, Huang S, Chung CCY, Chan MCY, Pajusalu S, et al. A three-year follow-up study evaluating clinical utility of exome sequencing and diagnostic potential of reanalysis. Npj Genom Med. 2020;5:37 https://doi.org/10.1038/s41525-020-00144-x
doi: 10.1038/s41525-020-00144-x
pubmed: 34504102
pmcid: 7484757
Li J, Gao K, Yan H, Xiangwei W, Liu N, Wang T, et al. Reanalysis of whole exome sequencing data in patients with epilepsy and intellectual disability/mental retardation. Gene. 2019;700:168–75. https://doi.org/10.1016/j.gene.2019.03.037
doi: 10.1016/j.gene.2019.03.037
pubmed: 30904718